Solventum Corporation
Every calculator, already run for SOLV
Open the full toolkit →You have the numbers on SOLV. Get the argument.
A written report on which of these readings actually decide the outcome for Solventum Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering SOLVAnalyst Price Target Disagreement for Solventum Corporation
Wall Street's bull case implies +27% from the current price; the bear case implies -21%. A 48% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for SOLV
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Solventum Corporation
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides d…
SOLV — frequently asked
Is SOLV a buy right now?
Wall Street's consensus rating on Solventum Corporation is Buy across 15 analysts, with a mean price target of $93.92 (+6% vs. the current $88.84). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is SOLV overvalued?
SOLV trades at 10.9x trailing earnings, against a DCF fair value of $91 per share. The current price implies 6% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is SOLV's next earnings date?
Solventum Corporation is next scheduled to report earnings around Nov 5, 2026. A full SOLV research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Solventum Corporation?
Analysts covering Solventum Corporation (SOLV) range from a bear-case target of $70.00 to a bull-case high of $113.00, with a mean consensus target of $93.92 across 13 analysts. The spread of $43.00 (48% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Solventum Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Solventum Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SOLV research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Solventum Corporation, in minutes. 3 free reports included with every account — no credit card required.